| Name |
CAS |
MF |
MW |
Single-letter sequence |
Three-letter sequence |
Number of AA |
Type |
Inquiry |
| NOTA-Pep-1L |
|
C84H139N27O25S3 |
2023.36 |
H2N-ACGEMGWVRCGGGS-Ahx-K-K(NOTA)-NH2 |
H2N-Ala-Cys-Gly-Glu-Met-Gly-Trp-Val-Arg-Cys-Gly-Gly-Gly-Ser-Ahx-Lys-Lys(NOTA)-NH2 |
17 |
IL13RA2 receptor–targeting peptide |
|
| CAQK peptide |
2088281-24-5 |
C17H31N5O7S1 |
449.52 |
H2N-CAEK-OH |
H2N-Cys-Ala-Glu-Lys-OH |
4 |
|
|
| TCP-2 |
|
C37H53N11O17S2 |
988.01 |
H2N-CSNSDWSSC-OH |
H2N-Cys-Ser-Asn-Ser-Asp-Trp-Ser-Ser-Cys-OH |
9 |
|
|
| APT STAT3 |
1345420-96-3 |
C158H205N39O36 |
3226.56 |
H2N-HGFQWPGSWTWENGKWTWKGAYQFLK-OH |
H2N-His-Gly-Phe-Gln-Trp-Pro-Gly-Ser-Trp-Thr-Trp-Glu-Asn-Gly-Lys-Trp-Thr-Trp-Lys-Gly-Ala-Tyr-Gln-Phe-Leu-Lys-OH |
26 |
STAT3-binding peptide |
|
| MLC |
|
C103H146N24O18S2 |
2072.54 |
H2N-MLALLGWWWFFSRKKC-OH |
H2N-Met-Leu-Ala-Leu-Leu-Gly-Trp-Trp-Trp-Phe-Phe-Ser-Arg-Lys-Lys-Cys-OH |
16 |
Mitochondria-targeting peptide |
|
| RTSPSSR |
1995062-44-6 |
C30H55N13O12 |
789.84 |
H2N-RTSPSSR-OH |
H2N-Arg-Thr-Ser-Pro-Ser-Ser-Arg-OH |
7 |
|
|
| CooP |
1192864-27-9 |
C32H57N9O11S |
775.91 |
CGLSGLGVA |
Cys-Gly-Leu-Ser-Gly-Leu-Gly-Val-Ala |
9 |
Linear glioblastoma-targeting peptide |
|
| STC |
|
C29H55N13O12S1 |
809.89 |
H2N–STCTRSR–OH |
H2N–Ser–Thr–Cys–Thr–Arg–Ser–Arg–OH |
7 |
LGR5-targeting peptide |
|
| SV40 T-Ag-derived NLS peptide |
105425-98-7 |
C66H111N19O18S |
1490.77 |
PKKKRKVEDPYC |
Pro-Lys-Lys-Lys-Arg-Lys-Val-Glu-Asp-Pro-Tyr-Cys |
12 |
Nuclear localization signal peptide |
|
| Aminopeptidase N Ligand (CD13) NGR peptide |
760947-20-4 |
C20H34N10O8S2 |
606.68 |
CNGRCG |
Cys-Asn-Gly-Arg-Cys-Gly |
6 |
CD13–targeting peptide |
|
| Rabies Virus Matrix Protein Fragment (RV-MAT) |
1023648-37-4 |
C135H232N44O47S |
3255.64 |
MNLLRKIVKNRRDEDTQKSSPASAPLDDG |
Met-Asn-Leu-Leu-Arg-Lys-Ile-Val-Lys-Asn-Arg-Arg-Asp-Glu-Asp-Thr-Gln-Lys-Ser-Ser-Pro-Ala-Ser-Ala-Pro-Leu-Asp-Asp-Gly |
27 |
AChR–targeting peptide |
|
| GB-6 |
2413262-74-3 |
C32H45N11O8 |
711.77 |
Q-{Htp}-{β-Ala}-{Nva}-GH-NH2 |
Gln-{Htp}-{β-Ala}-{Nva}-Gly-His-NH2 |
6 |
GRPR–targeting peptide |
|
| LyP-2 |
850859-24-4 |
C37H69N17O12S2 |
1008.18 |
CNRRTKAGC |
Cys-Asn-Arg-Arg-Thr-Lys-Ala-Gly-Cys |
9 |
|
|
| LyP-1 |
454487-07-1 |
C36H65N17O12S2 |
992.14 |
CGNKRTRGC |
Cys-Gly-Asn-Lys-Arg-Thr-Arg-Gly-Cys |
9 |
Tumor-targeting peptide |
|
| Anditixafortide (Pentixather) |
1821136-83-7 |
C60H79IN14O14 |
1347.26 |
cyclo(Nal-Gly-(3-I-d-Tyr)-(N-Me-Orn(AMBA-DOTA))) |
cyclo(Nal-Gly-(3-I-d-Tyr)-(N-Me-Orn(AMBA-DOTA))) |
|
CXCR4-targeting peptide |
|
| PSMA-1 |
2042750-71-8 |
C70H122N24O19 |
1603.87 |
GRFLTGGTGRLLRIS |
Gly-Arg-Phe-Leu-Thr-Gly-Gly-Thr-Gly-Arg-Leu-Leu-Arg-Ile-Ser |
15 |
PSMA targeting peptide |
|
| 293P-1 |
1465746-23-9 |
C65H99N21O17 |
1446.61 |
SNNNVRPIHIWP |
Ser-Asn-Asn-Asn-Val-Arg-Pro-Ile-His-Ile-Trp-Pro |
12 |
Hepatocytes targeting peptide |
|
| CVRARTR |
Not specified |
C33H64N16O9S |
860.48 |
CVRARTR |
H2N-Cys-Val-Arg-Ala-Arg-Thr-Arg-OH |
7 |
PD-L1–targeting peptide |
|
| SL022 |
|
C41H63N9O10 |
841.99 |
H2N–THYPIVI–OH |
H2N–Thr–His–Tyr–Pro–Ile–Val–Ile–OH |
7 |
CD38-targeting peptide |
|
| cyclo(RGDfC) |
862772-11-0 |
C24H34N8O7S |
578.64 |
cyclo(RGDfC) |
cyclo(Arg-Gly-Asp-DPhe-Cys) |
5 |
Tumor-targeting peptide |
|
